Pharmaceutical composition of 1-[2-(1-methylimidazol-4-yl)ethyl]perhydroazine-2,6-dione
RU2865695C1Active Publication Date: 2026-07-07OBSHCHESTVO S OGRANICHENNOJ OTVETABTVENNOSTJU VALENTA INTELLEKT +1
Patent Information
- Application Number
- RU2025105796
- Authority / Receiving Office
- RU · RU
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2025-03-12
- Publication Date
- 2026-07-07
- Estimated Expiration
- 2045-03-12
Smart Images
Figure 00000001
Abstract
FIELD: chemical-pharmaceutical industry.SUBSTANCE: pharmaceutical composition in powder form and medicinal product containing 1-[2-(1-methylimidazol-4-yl)ethyl]perhydroazine-2,6-dione or its pharmaceutically acceptable salt. A pharmaceutical composition in powder form with antiviral activity, containing 1-[2-(1-methylimidazol-4-yl)ethyl]perhydroazine-2,6-dione or a pharmaceutically acceptable salt thereof in an amount of 0.5–10.0 wt.% and excipients including one or more fillers selected from mannitol, maltodextrin or a mixture thereof, in an amount of 85.0–99.0 wt.% and a sweetener in an amount of 0.1–5.0 wt.%, as well as a medicinal product in powder form for the preparation of a solution for the treatment and / or prevention of viral respiratory diseases, containing the above pharmaceutical composition.EFFECT: high stability, low hygroscopicity, good flowability and mixing homogeneity, as well as hypoallergenicity and the possibility of use in pediatrics.13 cl, 4 tbl, 3 ex
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Pharmaceutical formulations and methods for treating respiratory tract infections
EP2315580A1
MEDICINE FOR THE TREATMENT AND PREVENTION OF DISEASES OF THE UPPER AND LOWER RESPIRATORY WAYS OF VARIOUS ETIOLOGY, ITS APPLICATION AND THE METHOD OF TREATMENT ON ITS BASIS
RU2014136096A
New compositions based on furazidin and methods for their preparation
RU2019110218A
Use of glutarimide derivative for therapy of diseases associated with aberrant activity of interleukin-6
RU2774928C2
Novel crystalline form of 1-[2-(1-methylimidazole-4-yl)ethyl]perhydroazine-2,6-dione and pharmaceutical use thereof
WO2023249516A1